The Director, HTA, Value & Evidence (HV&E) – Breast Cancer will support the strategic goals of the Oncology Division by driving optimal patient access for Pfizer’s portfolio of breast cancer medicines, with a focus on Ibrance.
Base: $176,600.00 - $294,300.00; Bonus/Equity: 20.0% bonus target; Benefits: Comprehensive and generous benefits package
Must-have
Nice-to-have
Permanent work authorization required